david: you teamed up for the corona vaccine with sanofi. which is another large pharmaceutical company. why did you team up with someone else? you are the biggest manufacturer vaccines. could you not have done this yourself? emma: it is one of the great things we have seen in many industries through the pandemic, is this incredible collaboration against a common competitor, or enemy. when we announced our approaches to vaccine development in the beginning of february, we said our best chance of contributing gsk's technology and know-how was to offer our technology which helps make other vaccines more effective. a technology that has been proven in pandemics to any credible partners. we have three vaccines partnered in the clinic with others, including sanofi, because that technology is proven in pandemics to work on older people. it is a more effective way to get to scaled manufacturing, which is the other real challenge. we need to probably provide up to 14 billion doses with two dose vaccines to protect the world. as well as getting to a

también otros que trabajan en vacunas son glaxo welcolme sanofi >> cuando se trata de ir al dentista, se ve obligado a cerrar por el covid-19 >> al llegar el paciente le tomamos la temperaturas le damos gel desinfectantes le damos el cuestionario para saber si ha tenido síntomas. >>el covid-19 nos cambio la vida a todos, adaptándonos a una nueva realidad. > >una vez ingresa, le pedimos que se lave las manos. >> lo que ha cambiado en tiempo de pandemia es que solo vemos un paciente a la vez, no citamos un pacientes cada hora, dejamos espacios de media hora. >> cada mañana el doctor flores llega a su consultorio en napa, donde obtuvieron permiso para abrir clínicas siguiendo estrictos lineamientos de covid-19. >> yo había abierto mi consultorio recién en noviembre pasado. >> el dentista antes de acercarse al paciente se coloca un gorro sobre su cabeza, mascarilla, basta desechable, mascarilla que cubre ojos y la cara y las manos las cubre con guantes desechables. >> también hacemos una limpieza detallada de las áreas comunes. un aseo que requiere una inversión en productos especializado

and japan have also got hefty orders in and finally the sanofi g s k vaccine hopeful is also very much in demand with the e.u. ordering yet again 300000000 doses the us 100000000 and the u.k. 60000000 on this let's speak to craig earlier who is a senior market analyst at craig thanks for joining us does this announcement from pfizer and by on sec give them a major advantage over the other vaccine produces. it gives them an advantage in that it looks like they're going to be the 1st to market so that means that they are going to be highest in the money in the early days and obviously with this process there is no guarantees so just because an oxford university with an old is a far along in the process until actually gets regulator approval is no guarantee that it's going to so 1st the market effectively just means that it's the only counted out there for now so to an extent you do get a slight advantage that said there are number of different vaccines potential vaccines out there that will be flooding this market but it's not a small market this is an entire global population will be ne

charles, don't count out sanofi.ovavax and sanofi have a vaccine in the works that is month or two behind, like the shingles vaccine we're using very successfully. johnson & johnson, astrazeneca, moderna is of course making a very similar vaccine to pfizer. those are the names you have to remember. but the pfizer is now at the front of the line. charles: doc, i have a minute to go if i could squeeze in two questions. first you already talked about how this pfizer vaccine works. it is unique. rna-dna approach. what other ailments or diseases could this benefit this, approach? >> well they're looking, they're looking at that for all types of diseases. everything from ebola to tuberculosis to hiv/aids. all of these diseases that we don't have an effective vaccine for. this is a brand new platform. tell you what is exciting about it. charles, it doesn't use the virus itself. it use as messenger to signal your cells to make a protein that the virus has. no virus, you don't get sick from it. you may get some side-effects t

recombinant protein platform, with one vaccine from novavax and another one from a partnership between sanofi and glaxosmithkline. are now innes clinical development stages and four of them are in phase three trials. completedfectively enrollment in the phase three trial and one of the two announced on monday, thrilling information, they had 90% efficacy. demonstrating that vaccination is possible against covid-19. that the kind of choices we have made in terms of the antigens was effective, and made us other vaccines may also be effective. moderna, the other company with a vaccine in a similar platform technology, announced that they have achieved the number of cases in their trial to allow for analysis, and i would expect that probably next week, we may hear other good information regarding the vaccine. the two other vaccines in phase , the j&j vaccine and the astrazeneca vaccine, have recruited a few thousand subjects in their trials. i would like to invite as many americans as possible who would like to volunteer to participate in these clinical trials, as that is the only way we are able

called novavax and another one from a partnership between sanofi and glaxosmithkline.rial.aand one of the two has these vaccines are now six vaccines are all in the clinical development stages, and four of them are in phase three trials. and of the four that are in phase three trials, two have effectively completed enrollment in the phase three trial. and one of the two has announced on monday to, i think, thrilling information that they had 90 percent efficacy that was the pfizer vaccine demonstrating that vaccination is possible against covid-19, that the kind of choices we have made in terms of the antigen selected was effective, and made us optimistic that other vaccines may also be effective. on wednesday, the same week, just this wednesday, moderna, the other company with the vaccine using similar platform technology, messenger rna announced that they have achieved the number of cases in their trial to allow for a first interim analysis, and i would expect that shortly probably next week we may hear what i hope to be another very good information regarding an eff

andourse you have glaxo sanofi working on the traditional vaccine starting in 2021.am, what can you tell us about modernity? this week was all about pfizer. it seems we are expecting some kind of trial analysis from moderna. pfizer andsurpass give us better news? wouldoing beyond the 90% be amazing, therefore, unlikely. one case in one group extra or less early changes on these low numbers of cases, the statistics that come out. if they come out was something in the 80% to 90% range, i would be very happy. francine: time, i can't say enough about how much i love speaking to sam. he knows everything. we were talking about testing yesterday and the difference between antigen. is it the same basis? one could be quicker? is it just a different premise? sam: they do have slight differences. the basics are pretty much the same. when you look at the data in the earlier trials, some differences emerged. i asked pfizer why they had a slight difference. they said, we think we know the answer but we are not ready to discuss it yet. some minor differences. whether that means any

for it then it's the delivery of it and so forth these are the kinds of companies, glaxosmithkline, sanofi, these are the guys that actually get it out there, scott, in the sorts of doses that are in the -- if you need a booster shot, 30 billion doses because we're talking in the neighborhood of 15 billion folks need this and that second booster shot and so forth to carry them on. i think those are stocks that have not been talked about enough they deserve some as well. like joe said, not just the biotechs some big pharmas do the heavy lifting. >> i want to get back to something city of said earlier as we have this conversation about the transition and how messy it feels right now and how messy it could still become, there are several weeks between now and january 20th, let's assume just for this conversation's sake that the transition happens that we have a transition. >> i know how far fetched that seems to have a conversation about that. >> and then you get back to a goldilocks scenario. a biden president, maybe a republican senate, under that scenario you have no tax hikes, the likes o

then there's the protein subunits with novavax and sanofi. now five of them are actually in , phase 3 trial. as i mentioned, two of them, the moderna and the pfizer one, results are in. a week ago, this past monday, pfizer announced that in their trial they had a situation where there were, i believe, four infections in the vaccine group -- actually, five infections in the vaccine group and 90 in the placebo, now they came out literally today with the announcement that that's a 95% efficacy. in the moderna trial, which was just announced a couple of days ago, they again had the same sort of breakdown, five in the vaccine, 90 in the placebo and 94.5% efficacy. of note in that trial a question had been asked, does it really protect against severe disease? in that trial, there were zero severe cases in the vaccine group and 11 severe cases in the placebo group. so what we're dealing with now is a brand new platform that many people had concern about because it was a new platform which clearly has shown a very striking efficacy signal almost iden

then there's the protein subunits with novavax and sanofi. five of them are actually in phase 3 trial. as i mentioned, two of them, the moderna and the pfizer one, results are in. a week ago, this past monday, pfizer announced that in their trial they had a situation where there were, i believe, four infections in the vaccine group -- actually, five infections in the vaccine group and 90 in the placebo, now they came out literally today with the announcement that that's a 95% efficacy. in the moderna trial, which was just announced a couple of days ago, they again had the same sort of breakdown, five in the vaccine, 90 in the placebo and 94.5% efficacy. of note in that trial a question had been asked, does it really protect against severe disease? in that trial, there were zero severe cases in the vaccine group and 11 severe cases in the placebo group. so what we're dealing with now is a brand new platform that many people had concern about because it was a new platform which clearly has shown a very striking efficacy signal almost identical

after that, sanofi and novavax, getting those into clinical trials and bringing those online.he had it exactly correct. >> so in regards to months, though, we know that front line health care workers will be the first folks getting this vaccine. if you are a regular ordinary american, when could you expect to see this vaccine? >> yeah. i would tell you that the bottom line is right after the first part of the second quarter. start thinking about april or may timeframe, we will have the massive amount of vaccines necessary to ensure the rest of america is covered down. early and often up front we'll have smaller doses, which we will prioritize. but later on, starting the second quarter, we'll have enough for the rest of americans to receive vaccines. >> so a lot of folks are less worried about urban areas because they have the resources to handle many of these vaccines, especially with the pfizer vaccine. they have the resources to keep those vaccines in those deep freeze environments. it's the rural areas that a lot more folks are worried about. i want to read some of you from

. >> reporter: the third is a familiar technology being used by sanofi, glass sew smi glaxose skippingtep requiring our cells to make the spike protein. >> it's the way we make the human papillomavirus, hepatitis b, one of the flu vaccines he says each may have benefits and drawbacks. one might work better for older or high-risk people, but we won't know until the third phase trials is complete for all of them. >> the proof is in the pudding the pudding is the phase three trials which of the vaccines will be the best in we'll find out >> guys, we learned this week the pfizer vaccine looks to be very effective folks like dr. fauci tell us because all of these vaccines have a similar approach, that spike protein, the pfizer news is good news for everything coming behind it so, we are hopeful and we should see the moderna data pretty soon kel kelly? >> that was a great explainer, meg. stay right there for more on how these vaccines work and also what we can expect in terms of the challenge of getting people to take one for covid when it's approved, let's also bring in dr. lloyd minor, dea

and japan have also got hefty orders in and finally the sanofi g s k vaccine hopeful is also very much in demand with the e.u. ordering yet again 300000000 doses the u.s. 100000000 and the u.k. 60000000. well on this let's speak to craig who is a senior market analyst at craig thanks for joining us does this announcement from pfizer and by on sac give them a major advantage over the other vaccine produces it gives them an advantage in that it looks like they're going to be the 1st to market so that means that they are going to be highest in the money in the early days and obviously with this process there is no guarantees so just because an oxford university and all those are far along in the process until i actually get regulator approval is no guarantee that it's going to so 1st a market effectively just means that it's the only candidate out there for now so to an extent you do get a slight advantage that will divert late so there are number of different vaccines potential vaccines out there that will be flooding this market but it's not a small market this is an entire global popul

one so far to test a single shot vaccine the others require two doses behind nose are novavax and sanofi with trials that could start by the end of the year they all target the coronavirus in the same way, focusing on its spike protein. but they do it slightly differently. moderna rely on messenger rna and have been able to move the fastes fastest. the others employed a tried and true approach which takes long story develop. success for multiple vaccines is key for large numbers of americans to get vaccinated quickly. together they are expected to have enough supply for 20 million americans this year. dr. thank you very much fauci says if others are successful there should be enough for everyone in the u.s. who wants to get vaccinated so who gets it first. a cdc advisory group will make the final call but the national academies of science, engineering and medicine have laid out a framework top of the list, high risk health workers and first responders then people with health conditions that put them at significantly higher risk and older adults living in congregant settings like nursing

and sanofi-aventis glaxosmithkline combination.wo more to be available late january, february and then the last two available probably somewhere in april, may. reporter: back to moderna though for a second. this was the initial reaction from president trump, taking to twitter, moderna applying for emergency vaccine approval. fda must act quickly. however, david, the fda has been pretty clear on this when it comes to the eu a process. when an eua is submitted to them it will be likely weeks to review. they want to look at all the data before them. they want this vetted, thorough and transparent. neil: david: deregulation one of the key components of blake, thank you very much. stocks not reacting like the last few mondays to the vaccine news, most likely fears spread by dru fauci and others forecast ing new covid spikes for the month of december. we have michelle snyder and money map press chief strategist shah ghailani. talk about an a-team, we have it here. shah, first to you. i'm talking about the negative numbers in the dow, is

we signed with astrazeneca, johnson & johnson, sanofi and are about to sign with pfizer and biontech.at the present we have a portfolio that has six potential vaccines. maria: a total of 6 -- >> we could expand it. maria: you are looking potentially at -- >> we will leave no stone unturned. mentionednow you europe will have to approve it. we have seen in the united states they get done quickly. in europe how quickly could we see that green light to make sure this can be sold and given to people? >> any medicine or vaccine that is used in the european union needs market authorization from the european medicine agency. this is important in terms of independent scientific study for effectiveness and safety. this will be done as quickly as possible. the european medicine agency is already looking at a rollout review for this vaccine, and is ready to receive the application when it comes. there will be no delay, but we will not cut corners with safety and efficacy issues. anna: no cutting corners from the eu health commissioner. ofutes to go until the start thursday's equity session. we wi

we'll need merck, sanofi and some version to allow everybody in the world who wants to get vaccinatedinated w.h.o. official on the wire as we speak and says we could be in a position with a vaccine roll out by march 2021. >> that's great. that's earlier than i thought we would hear that's good news >> thank you back to stocks this morning. happy monday >> david, looking at a note. their line is at least as good as the best cased scenario would have hoped for >> i think it is it seems to have surprised the smartest guys out there and should surprise us too we are seeing that in the market this is a big turn what's really important is it is on the horizon we are starting to see the dollar with stocks something we've highlighted a lot. when you get a real recovery, the dollar continues to go up as people go higher as opposed to the fed being the driver and driving real rates down and the dollar weakening and that pushing the stocks up the handoff from the fed to the economy, you can see it and it is a really interesting feature of what we are seeing today. that is an important thing to w

and is the case with the other four companies, pfizer, sorry, j&j, astrazeneca, novovax and so no sanofi they have to file within the month of november or extremely early in the month of december i think every day unfortunately 2,000 people, 1500 people die, almost 200,000 people are infected every day, every hour counts if the time difference in review of the file is over five or six days, the fda will hold a review of the pfizer v er vaccine and days later for the moderna vaccine. this will pan out as the reviews go on. at this stage, it is more likely they will make them a few days apart. >> i'm completely baffled and confused we're old enough to remember when we had to go get our polio shots, we went to our schools, there they were. and then we got our sugar cubes. and we were most grateful because before this, we were afraid to go outside, we would get polio. what a beautiful way to be able to do this it is not being done we had the military on "60 minutes" say we're ready to get this to everyone who needs it. we are so, so organized. everyone is going to get it. we have u.p.s. sayi

and sanofi glaxosmithkline collaboration.es all in the clinic, two shortly to be available, two more to be available probably late january, february and then the last two to be available probably somewhere in april, may. maria: what was critical in terms of mobilizing this industry? i mean, look, you ho how imports it to mobilize the pharmaceutical industry? president trump told us back in march or april when we were really in the depths of the beginning of this that we would have a vaccine by year-end and his critics mocked him. in fact, here we are, talking about all of this success in terms of the vaccine, thanks to him and you and your team. what was it that enabled us to get a vaccine on the market so quickly? >> well, it's really first a vision, visionary approach to putting together the academic science, the industry, large and small, biotech and big pharma, the army, and the u.s. government. and i think this coalition together has been integrated in their operation warp speed, hugely aligned all resources put together